CA1047919A - Pharmaceutical insulin preparations having antidiabetic activity and process for their manufacture - Google Patents
Pharmaceutical insulin preparations having antidiabetic activity and process for their manufactureInfo
- Publication number
- CA1047919A CA1047919A CA224,590A CA224590A CA1047919A CA 1047919 A CA1047919 A CA 1047919A CA 224590 A CA224590 A CA 224590A CA 1047919 A CA1047919 A CA 1047919A
- Authority
- CA
- Canada
- Prior art keywords
- insulin
- preparation
- ulin
- range
- des
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 229940125396 insulin Drugs 0.000 title claims abstract description 33
- 102000004877 Insulin Human genes 0.000 title claims abstract description 28
- 108090001061 Insulin Proteins 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 230000003178 anti-diabetic effect Effects 0.000 title abstract 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000007900 aqueous suspension Substances 0.000 claims abstract 2
- 239000011701 zinc Substances 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims 3
- 239000004026 insulin derivative Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 240000003550 Eusideroxylon zwageri Species 0.000 description 41
- 150000002500 ions Chemical class 0.000 description 15
- 101150106193 tal gene Proteins 0.000 description 11
- 239000007788 liquid Substances 0.000 description 6
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 241001630921 Chlorida Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101100478173 Drosophila melanogaster spen gene Proteins 0.000 description 1
- 241000090179 Lorio Species 0.000 description 1
- 241000489861 Maximus Species 0.000 description 1
- 241001068914 Melicope knudsenii Species 0.000 description 1
- 101100513476 Mus musculus Spen gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- VXEAYBOGHINOKW-UHFFFAOYSA-N cyclobenzaprine hydrochloride Chemical compound Cl.C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 VXEAYBOGHINOKW-UHFFFAOYSA-N 0.000 description 1
- OWZREIFADZCYQD-NSHGMRRFSA-N deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- HVFSJXUIRWUHRG-UHFFFAOYSA-N oic acid Natural products C1CC2C3CC=C4CC(OC5C(C(O)C(O)C(CO)O5)O)CC(O)C4(C)C3CCC2(C)C1C(C)C(O)CC(C)=C(C)C(=O)OC1OC(COC(C)=O)C(O)C(O)C1OC(C(C1O)O)OC(COC(C)=O)C1OC1OC(CO)C(O)C(O)C1O HVFSJXUIRWUHRG-UHFFFAOYSA-N 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 101150040618 talB gene Proteins 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2418218A DE2418218A1 (de) | 1974-04-13 | 1974-04-13 | Neue arzneimittel-zubereitung mit antidiabetischer wirkung |
| DE19742459515 DE2459515C3 (de) | 1974-12-17 | 1974-12-17 | Arzneimittelzubereitungen mit antidiabetischer Wirkung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1047919A true CA1047919A (en) | 1979-02-06 |
Family
ID=25766977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA224,590A Expired CA1047919A (en) | 1974-04-13 | 1975-04-11 | Pharmaceutical insulin preparations having antidiabetic activity and process for their manufacture |
Country Status (11)
| Country | Link |
|---|---|
| AU (1) | AU500430B2 (enExample) |
| CA (1) | CA1047919A (enExample) |
| EG (1) | EG12098A (enExample) |
| ES (1) | ES436398A1 (enExample) |
| FI (1) | FI751084A7 (enExample) |
| FR (1) | FR2267116B1 (enExample) |
| GB (1) | GB1492837A (enExample) |
| IE (1) | IE40985B1 (enExample) |
| IL (1) | IL47043A (enExample) |
| LU (1) | LU72269A1 (enExample) |
| NL (1) | NL7504165A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294656B1 (en) | 1995-07-25 | 2001-09-25 | Novartis Corporation | Transforming growth factor β crystals |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1560232A (en) * | 1977-02-01 | 1980-01-30 | Novo Industri As | Biphasic insulin preparations comprising crystalline insulin and monodesamido insulin |
| DE3717370A1 (de) * | 1987-05-22 | 1988-12-01 | Hoechst Ag | Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus |
-
1975
- 1975-03-31 EG EG178/75A patent/EG12098A/xx active
- 1975-04-07 GB GB14079/75A patent/GB1492837A/en not_active Expired
- 1975-04-07 IL IL47043A patent/IL47043A/xx unknown
- 1975-04-08 ES ES436398A patent/ES436398A1/es not_active Expired
- 1975-04-08 NL NL7504165A patent/NL7504165A/xx not_active Application Discontinuation
- 1975-04-10 FI FI751084A patent/FI751084A7/fi not_active Application Discontinuation
- 1975-04-11 IE IE832/75A patent/IE40985B1/xx unknown
- 1975-04-11 LU LU72269A patent/LU72269A1/xx unknown
- 1975-04-11 CA CA224,590A patent/CA1047919A/en not_active Expired
- 1975-04-11 AU AU80073/75A patent/AU500430B2/en not_active Expired
- 1975-04-14 FR FR7511535A patent/FR2267116B1/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294656B1 (en) | 1995-07-25 | 2001-09-25 | Novartis Corporation | Transforming growth factor β crystals |
Also Published As
| Publication number | Publication date |
|---|---|
| AU8007375A (en) | 1976-10-14 |
| IE40985B1 (en) | 1979-09-26 |
| NL7504165A (nl) | 1975-10-15 |
| LU72269A1 (enExample) | 1977-02-03 |
| FR2267116A1 (enExample) | 1975-11-07 |
| ES436398A1 (es) | 1977-05-01 |
| AU500430B2 (en) | 1979-05-24 |
| IL47043A0 (en) | 1975-06-25 |
| FR2267116B1 (enExample) | 1978-10-06 |
| FI751084A7 (enExample) | 1975-10-14 |
| IE40985L (en) | 1975-10-13 |
| IL47043A (en) | 1978-06-15 |
| GB1492837A (en) | 1977-11-23 |
| EG12098A (en) | 1980-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4027046A (en) | Fining with aluminate-modified silica sol | |
| SA97180104B1 (ar) | تركيبات متضمنة على عامل مضاد للفطريات antifungal agent acetate agent ومنظم من الخلات acetate buffer | |
| CA1047919A (en) | Pharmaceutical insulin preparations having antidiabetic activity and process for their manufacture | |
| EP0913152A1 (de) | Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum | |
| Craig et al. | Bacitracin A. Isolation by counter double-current distribution and characterization | |
| EP3610857A1 (en) | Suspension comprising aluminum hydroxide and magnesium hydroxide and preparation method therefor | |
| Wurster et al. | Investigation of drug release from solids IV. Influence of adsorption on the dissolution rate | |
| SU1706372A3 (ru) | Способ получени водных растворов винкристина или винбластина | |
| US4390694A (en) | Method for preparing stable crystals of salt of Ceftizoxime | |
| CN111821258A (zh) | 一种复方恩诺沙星口服液及其制备方法 | |
| US6747012B1 (en) | Crystalline anthracycline antibiotic and process for producing the same | |
| CN113318074A (zh) | 一种苯磺顺阿曲库铵注射液的制备方法 | |
| CN110845384A (zh) | 一种钛络合药物的解离方法及其应用 | |
| RU2795006C2 (ru) | Суспензия, содержащая гидроксид алюминия и гидроксид магния, и способ ее получения | |
| Bravo et al. | The chloro complexes of gold (I) in acetonitrile and comparison with those of copper (I) and silver (I) | |
| RU2021345C1 (ru) | Водка "золото россии" | |
| Goldstein | The iodide‐iodine solubility relation | |
| RU2141515C1 (ru) | Водка "телецкая золотая" | |
| CN102716096B (zh) | 一种含有头孢替安的药物组合物 | |
| JP4963776B2 (ja) | 抗真菌活性増強型組成物及び抗真菌活性増強方法 | |
| US20130225869A1 (en) | Stabilized 3,3 dialkoxy-1-propene - preparation | |
| CN115137700A (zh) | 一种降低失水率的右美托咪定水溶液制剂 | |
| Tattersfield et al. | Extracts of pyrethrum: permanence of toxicity and stability of emulsions | |
| RU2079306C1 (ru) | Фармацевтическая композиция и способ ее получения | |
| AT337199B (de) | Verfahren zur herstellung von neuen, tricyclischen kondensierten imidazol-derivaten |